Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.

Advanced Medicine

Manufacture Biosimilars

New Decade, New Hope

| Stephanie Sutton

Cures for all presents a real focus for the next decade – but companies must be rewarded for their work.

Discovery & Development Drug Discovery

LEGO Linkers for ADCs

| Maryam Mahdi

A new computational tool could help improve the stability and predictability of ADCs.

Business & Regulation Business Practice

Sitting Down With... Jane Osbourn

| James Strachan

Jane Osbourn talks about the potential of the UK's cell and gene therapy space.

Manufacture Advanced Medicine

The CRISPR Toolbox

| Garrett Rettig

"Moving beyond Cas9 may be the secret to reducing CRISPR’s off-target effects," says Garrett Rettig.

Manufacture Advanced Medicine

Technology Leads the Way

| Dawne Shelton, Eli Heffner

Can new tools lower the hurdle of high manufacturing costs for cell and gene therapies?

Manufacture Technology and Equipment

The Innovation Awards 2019

After a vibrant year of advances in pharmaceutical development and manufacturing technologies, we present The Medicine Maker 2019 Innovation Awards.

Manufacture Advanced Medicine

Unprecedented Growth – and Challenges

| Philip W. Wills

Now that Gene therapy's promise has been shown, the industry must focus on improving the manufacturing process and bring down costs.

Manufacture Advanced Medicine

A Conference Season’s Greeting

| James Strachan

Glad tidings of progress and confidence this (conference) season! But let’s not dismiss the emerging skills challenge as “humbug.”

Manufacture Advanced Medicine

A British Success Story

| James Strachan

The UK’s CGT Catapult has played a significant role in building the strong advanced therapy ecosystem in the UK, the largest outside the USA.

Manufacture Advanced Medicine

Keeping up with the Usain Bolt of Biotech

| Emily Hopewell, Patrick Rivers

With many cell and gene therapies skipping phase III trials entirely, academics must get to grips with GMP early.


Latest White Papers

Early stage product development using laser diffraction analysis

| Contributed by Malvern Panalytical

Measurement of the concentration of Adeno-Associated Virus

| Contributed by Malvern Panalytical

All White Papers

Sister Publications

You might be interested in our Sister Publications:

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register